ABT vs ZBH: fair value comparison
Abbott Laboratories and Zimmer Biomet Holdings, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ZBH currently sits closer to the top of our discount ranking.
| ABT | ZBH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $112.47 | $100.91 |
| 12-month range | $87.78–$131.46 | $82.90–$105.01 |
| Sector rank | #43 of 113 Healthcare | #40 of 113 Healthcare |
| Quality grade | B | B |
| Momentum grade | — | B |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: ABT fair value analysis · ZBH fair value analysis